Treatment Considerations in KRAS NSCLC

Yale Cancer Center
A

KRAS G12C NSCLC Treatment Approach: Surveying OS Data, CNS Activity, Patient Selection, and How to Choose Between Available Agents

By Yale Cancer Center FEATURING Amin Nassar
By Yale Cancer Center FEATURING Amin Nassar
219 views
August 22, 2023
Comments 0
Login to view comments. Click here to Login
04:42

NSCLC Panel Discussion: Should a Patient With High PD-L1 Wait for Ge…

GRACE

K. Higgins, A. Desai, J. Lin, J. Reuss, P. Iyengar

285 views
06:29

WCLC 2023 Insights: "KRYSTAL-1 - Two-Year Follow-Up of Adagrasib Mon…

Insights from 2023 WCLC

S. Gadgeel

174 views
21:16

Targeted Therapies in Lung Cancer 2023: Translating Cancer Discovery…

GRACE

J. Sabari

150 views
07:34

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Tr…

Marcelo Negrao

473 views
17:07

NOS ASCO® 2023 Review: Targeting Advanced KRAS and EGFR Mutations in…

Nebraska Oncology Society

V. Lam

102 views
18:14

Understanding KRAS G12C Positive Lung Cancer

Janakiraman Subramanian

658 views
09:17

The Data on Novel KRAS G12C Inhibitors: Focus on Adagrasib

Shirish Gadgeel

342 views
33:14

Direct KRAS Inhibition in NSCLC: Past, Present, and Future

Benjamin Herzberg

250 views